SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Syncom Formulations (India) Ltd (SYNCOMF) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 524470 NSE: SYNCOMF | Pharmaceuticals & Drugs | Small Cap

Syncom Formulations Share Price

14.34 0.39 (2.80%)
As on 17-Apr'26 16:59

Syncom Formulations (India) Ltd (SYNCOMF)

BSE: 524470 NSE: SYNCOMF
Key Metrics
Market Cap
₹1,348 Cr.
P/E Ratio
19.55
Price to Book (P/B)
3.41
Price to Sales (P/S)
2.69
EV/EBITDA
13.93
Return on Capital Employed (ROCE)
18.66%
Current Price
₹14.3
Return on Equity (ROE)
15.61%
Return on Assets (ROA)
12.13%
Operating Profit Margin
11.6%
Net Profit Margin
10.56%
Gross Profit Margin
15.1%
Book Value per Share
₹4.2
Sales Growth (YoY)
79.15%
Sales Growth (3 Years)
28.2%
Operating Profit Growth (1 Year)
92.14%
Operating Profit Growth (3 Years)
38.73%
Net Profit Growth (1 Year)
106.9%
52-Week Low / High
₹10 / 23
Net Profit Growth (3 Years)
35.17%
Dividend Yield
0.00%
Promoter Holding
50.57%
Pledged shares (%)
of Promoter's holding (%)
0.00%

Check Before You Invest

Q.1 Revenue growth of Syncom Formulations (India) Ltd?
Syncom Formulations (India) Ltd revenue growth is 79.2% for FY-2025 , which is above its 5 year CAGR of 17.6% , indicating faster growth.
Q.1 Promoter shareholding and pledge status of Syncom Formulations (India) Ltd?
Promoters hold 50.57% of the Syncom Formulations (India) Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Revenue growth of Syncom Formulations (India) Ltd vs industry peers?
Syncom Formulations (India) Ltd revenue CAGR is 17.63% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Q.1 Which industry/sub-sector does Syncom Formulations (India) Ltd belong to?
Syncom Formulations (India) Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.1 Stock return of Syncom Formulations (India) Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 18.1% based on the current price.

DeciZen - make an informed investing decision on Syncom Formulations

Based on:

Overall Rating
Login to view analysis.

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Syncom Formulations (India) stock performance

Key Ratios
mw4me loader

Is Syncom Formulations (India) Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Syncom Formulations (India) Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 14.7%13.6%9.4%9.4%12.4%20.7%10.6%9.7%10.4%18.7%-
Value Creation
Index
0.10.0-0.3-0.3-0.10.5-0.2-0.3-0.30.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 184185159187206245220225258463501
Sales YoY Gr.-0.5%-14.2%17.7%10%19.1%-10.3%2.3%15%79.2%-
Adj EPS 0.10.10.10.10.20.40.20.20.20.50.7
YoY Gr.-7.7%-21.4%27.3%28.6%100%-44.4%-10%33.3%100%-
BVPS (₹) 1.41.51.61.71.92.32.52.73.13.64.2
Adj Net
Profit
10.410.78.611.114.328.517.517.222.345.369
Cash Flow from Ops. 24.116.9-1.64.35.9-2.116.310.5-5.923.3-
Debt/CF from Ops. 0.20.7-7.820.4-30.13.57.9-12.10.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.8%17.6%28.2%79.2%
Adj EPS 15.6%21.7%33.9%100%
BVPS11.2%14.1%12.8%18.7%
Share Price 18.8% 28.5% 32.5% -18.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
109.67.38.710.317.18.67.28.214.518.7
Op. Profit
Mgn %
9.18.97.46.38.215.59.18.910.811.614.6
Net Profit
Mgn %
5.75.85.55.9711.787.78.69.813.7
Debt to
Equity
0.10.10.10.100.40.30.30.30-
Working Cap
Days
18118418615114215424028623213299
Cash Conv.
Cycle
2825505561731111171207878

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials

Standalone Consolidated
TTM EPS (₹) 0.7 0.7
TTM Sales (₹ Cr.) 501 503
BVPS (₹) 4.2 4.2
Reserves (₹ Cr.) 301 303
P/BV 3.41 3.39
PE 19.55 19.55
From the Market
52 Week Low / High (₹) 10.21 / 23.46
All Time Low / High (₹) 0.14 / 27.94
Market Cap (₹ Cr.) 1,348
Equity (₹ Cr.) 94
Face Value (₹) 1
Industry PE 42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Syncom Formulations - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales184185159187206245220225258463
Operating Expenses + 167168147175189207200205231409
Manufacturing Costs30303334404741494748
Material Costs10710381107118120106101116267
Employee Cost 13141515161821243451
Other Costs 18221818152132303344
Operating Profit 17161212173820202854
Operating Profit Margin (%) 9.1%8.9%7.4%6.3%8.2%15.5%9.1%8.9%10.8%11.6%
Other Income + 33455712151317
Exceptional Items -0-0-00-0000-00
Interest 0000102341
Depreciation 3344444555
Profit Before Tax 16161213174126273265
Tax 653231266816
Profit After Tax 1011911142920202449
PAT Margin (%) 5.6%5.8%5.5%5.9%6.9%11.9%9.0%8.9%9.1%10.6%
Adjusted EPS (₹)0.10.10.10.10.20.40.20.20.30.5
Dividend Payout Ratio (%)15%15%0%0%0%0%13%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 109114122133146178217256286340
Share Capital 78787878787986949494
Reserves 313644556899131162192246
Debt +6121292625883724
Long Term Debt0000000000
Short Term Debt6121292625883724
Minority Interest0000000000
Trade Payables47322221202914201443
Others Liabilities 19201714162219172125
Total Liabilities 181179174176184292308377394412

Fixed Assets

Net Fixed Assets +46555848464447437278
Gross Block829298919395101102136146
Accumulated Depreciation37374043475154596368
CWIP 50100062600
Investments 2312211143646693
Inventories15101114162320212141
Trade Receivables464638414375687593107
Cash Equivalents 676896409681
Others Assets 3959596369741251397393
Total Assets 181179174176184292308377394412

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 2417-246-21610-623
PBT 16161213174126273265
Adjustment 10-0-1-1-2-7-6-3-11
Changes in Working Capital 125-10-4-6-294-3-27-16
Tax Paid -5-4-3-3-4-11-6-7-8-14
Cash Flow From Investing Activity + -23-8-222-75-27-4584-18
Capex 0-8-76-9-3-11-21-8-10
Net Investments -17-13-2-84-79-25-3878-24
Others -612657610141415
Cash Flow From Financing Activity + -2-2-2-0-772835-15-68
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000100
Interest Paid -0-0-0-0-0-0-1-3-4-1
Dividend Paid -2-2-20000-300
Others -1000-672940-11-67
Net Cash Flow -16-671-5-2163-63

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)9.919.567.338.7110.2418.0410.028.488.7115.61
ROCE (%)14.7213.589.439.3712.3920.7210.619.6810.3918.66
Asset Turnover Ratio1.151.030.91.071.141.030.730.660.671.15
PAT to CFO Conversion(x)2.41.55-0.220.360.43-0.070.80.5-0.250.47
Working Capital Days
Receivable Days76919677758811811611979
Inventory Days26252424262935333025
Payable Days11514112374647574625439

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Syncom Formulations (India) Ltd FAQs

The current trading price of Syncom Formulations on 17-Apr-2026 16:59 is ₹14.34.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Syncom Formulations stood at ₹1,348 Cr

The latest P/E ratio of Syncom Formulations as of 16-Apr-2026 is 19.55.

The latest P/B ratio of Syncom Formulations as of 16-Apr-2026 is 3.41.

The 52-week high of Syncom Formulations is ₹23.46 and the 52-week low is ₹10.21.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Syncom Formulations is ₹501 ( Cr.) .

About Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd was originally incorporated as Syncom Formulations (India) Private Limited in the state of Maharashtra on June 21, 1988 under the Companies Act, 1956. Further the status of company was changed to public limited company and thereby name of company changed to Syncom Formulations (India) Limited and a fresh certificate of change of name obtained on July 9, 1992.

The company was promoted by Kedarmal Bankda, Ajay Kumar Bankda & Vijay Kumar Bankda for manufacturing, marketing, dealership, importing, exporting & job work of pharmaceuticals, medicinal and other Industrial preparation & formulations under its own brands in ethical, OTC, generic and herbal market segment. The company came out with its Initial Public Offering in the Year 1994 hence obtained listing at BSE, DSE, ASE and MSE. However company has voluntarily de-listed its shares from ASE on July 8, 2004, MPSE on May 29, 2008 & DSE on September 2, 2004.

The company is engaged in the business of pharmaceutical formulations. It manufactures range of products in various dosage forms and markets them in various countries. In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures Injectibles, inhalers and ear/eye drops. In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in January 1994 was completed in 1995.

During the year 1997-98, the company has further diversified into ethical operations by introducing the range of prescription formulations. During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company introduced products in the generic, OTC and ethical divisions. During the year 2007-08 the company has further completed modernization and expansion of project in Pithampur unit, District Dhar, M.P with a total investment of Rs. 1516.62 Lakh.

Today, SFL stands as one of the fastest growing pharmaceutical company operating in more than 35 countries worldwide and has more than 150 products in various dosage forms which include tablets, capsules, dry syrups, and ointments/creams, dry powder Injections and ampoules and wide range of herbal products.

Syncom was keeping pace with the changing pharmaceutical scenario ventured into International market a decade ago. The International operations are managed from its International division located in Mumbai, commercial capital of India. Syncom today promotes all its generic, herbal and OTC range of products in the markets where it operates. Syncom's presence is felt in Asia, Africa, CIS, and Russia and Latin American countries. Mumbai Office also houses the Regulatory Affairs Department, which is well equipped with modern library, reference documents, and all other facilities to provide world-class registration dossiers.

Syncom's vision to globalise its herbal range of product has been vindicated by the excellent acceptance of these products by customers world over. Syncom has taken efforts to bring to mankind the goodness of AYURVEDA, the traditional Indian medicinal science through its unique range of herbal products used for various therapeutic and prophylactic purposes. Millions of healthy patients world wide, stand testimony to the alleviation of various disorders and improvement in their quality of life with products. The company presently exports goods to Guinea, Ghana, Kenya, Uganda, Sudan, Russia, Maldova, Tanzania, Africa, Azberjan, Nepal and Srilanka.

The company has been approved as a supplier to reputed hospitals and regulatory agencies including Central Medical Stores Organization of Gujarat Govt, Directorate of health services of Delhi Govt. and Central Govt. and supply to and registration of defense services is in its final stages. This results in generating substantial sales volume. Keeping in view the shifting consumer preferences for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Colo Vaporex, Colo Inhaler, Edicare, Attom Megacaps, Ecziguard and Yas antacid salt.

In 2012 Company incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates.

Product range of the company includes:

Generic

  • Tablets
  • Capsules
  • Liquid Orals
  • Vials
  • Eye / Ear Drops
  • Ampoules
  • Dry Powder Orals

Herbal Branded

  • Colo Vaporex
  • Colo Inhaler
  • Colo Mouth Gel
  • Fastac Ointment
  • Candid Balm
  • Saloni Cream
  • Borosyn Cream
  • Edicare Cream
  • Ecziguard Cream
  • Pyl Gel
  • Attom Cream
  • Attom Megacaps
  • Shilajit Capsules
  • Liovset Tonic
  • Colo Cough Syrup
  • Pudin Rahat
  • Syncom Gripe Water
  • Feelax Powder
  • Yas Antacid Salt

Branded Allopathic

  • Qudermis Cream
  • Silver Plus Cream
  • Aciril Tablets
  • Fastac tablets
  • Odynil Tablets
  • Palera Plus Tablets
  • Polyfer Tablets 50 mg
  • Polyfer tablets 100 mg
  • Syncal D Tablets
  • M - Dox DT Tablets
  • Synortin Tablets
  • Synospas Tablets
  • Tici Forte Tablets
  • Triple Action Tablets
  • Flusa Kit Tablets
  • HBC kit (Combikit of 4 Tablets)
  • NTB-4 Kit Tablets
  • Fresca Tablets
  • Thixim
  • Thixim Tablets
  • Anergy Cap's
  • Grosyn
  • Profeed
  • Q-Coril Cough Formula
  • Syncal D-B12 Syrup
  • Aciril Suspension
  • Anergy Syrup
  • Nutone Syrup
  • Thixim-I Injection
  • Thixim-I Injection
  • Ceftacom Injection
  • Ceftacom Injection
  • TD-Mox
  • Polyfer Drops
  • Revive

Achievements/ recognition:

  • GMP certification
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×